CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

CareDx Symposium to Highlight New Real-World Use Cases Using its Testing and Digital Solutions for Improved Patient Risk Management

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence and the fifth consecutive year as the Distinguished Founder’s Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium being held January 11 - 14, 2024 in Miami, Florida.

CareDx and research collaborators are sharing the latest clinical advances to help advance transplant patient care using CareDx’s non-invasive testing services and digital health solutions at the meeting.

“As a longtime supporter of ASTS, we are honored to continue our commitment as the Founder's Circle Sponsor. It is gratifying to witness the clinical use of our non-invasive molecular diagnostics, predictive modeling, and digital health tools make a tangible impact in advancing transplant patient care,” said Robert Woodward, PhD, Chief Scientific Officer at CareDx. “The real-world impact showcased in the presented case studies underscores our commitment to transforming transplant patient care for improved long-term outcomes.”

During its industry sponsored symposium, titled, “Real-World Use of AlloSure® in Identifying, Stratifying, and Mitigating Risk to Optimize Transplant Outcomes,” leading transplant experts will demonstrate how CareDx's molecular testing services, digital solutions, and risk assessment tools can improve access and outcomes within transplantation. The following speakers will also discuss the integration of these technologies into clinical practice and means for future development.

• Irene Kim, MD, FACS, Professor & Chair, Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center
• Matthew Cooper, MD, Chief of Division of Transplant Surgery, Director of the Solid Organ Transplant Service Line, Froedtert Memorial Lutheran Hospital and Children's Wisconsin

“I'm pleased to be part of CareDx's symposium to demonstrate how non-invasive molecular diagnostics and digital tools can provide new insights in managing high risk patients,” said Dr. Matthew Cooper. “I'll share how we utilize AlloSure to monitor and manage patients with delayed graft function, along with patient case examples showcasing our use of these innovative technologies to demonstrate their real-world impact on patient care.”

CareDx AlloSure data will also be featured in a presentation being delivered at the ASTS Research Grants session in a talk titled, “Using Phenotypic Precision Medicine to Individualize Immunosuppression Based on Quantifiable Markers of Immune Response and Allograft Injury.”

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s digital health solutions in kidney, heart, and lung transplant patients, including AlloSure, and its sponsorship of and participation at the 2024 ASTS Winter Symposium. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its digital health solutions including AlloSure, or its sponsorship and participation of the 2024 ASTS Winter Symposium; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, the quarterly report on Form 10-Q for the quarter ended September 30, 2023 filed by CareDx with the SEC on or about November 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111139097/en/